View in EDS PDF Full Text

Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States.

Saved in:
Bibliographic Details
Title: Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States.
Authors: Faught, E.
Source: Acta Neurologica Scandinavica: Supplementum. Dec2011 Supplement 192, Vol. 124, p29-35. 7p.
Subjects: Vigabatrin, Spasms, Treatment of epilepsy, Clinical trials, Drug abuse, Pure Food & Drug Act of 1906
Geographic Terms: United States
Abstract: Faught E. Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States. Acta Neurol Scand: 2011: 124 (Suppl. 192): 29-35. © 2011 John Wiley & Sons A/S. Vigabatrin is an antiepileptic drug used in more than 50 countries as adjunctive therapy for the treatment of refractory complex partial seizures (rCPS) in adults. First approved in the United Kingdom in 1989, vigabatrin was approved for use in the United States by the Food and Drug Administration in 2009. Although most clinical trials of vigabatrin have been conducted in Europe, three major trials, including two pivotal trials, were conducted in the United States. These trials have demonstrated efficacy and tolerability findings similar to those observed from the European trials. Results of the US trials have demonstrated vigabatrin to be an effective and generally well-tolerated therapy for rCPS in adults, with an optimal dosage of 3 g/day for most patients, and an onset of response generally within 2 weeks. This review focuses on the design and results of the three major US trials of vigabatrin in adults with rCPS. [ABSTRACT FROM AUTHOR]
Copyright of Acta Neurologica Scandinavica: Supplementum is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 67057761
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Faught%2C+E%2E%22">Faught, E.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Acta+Neurologica+Scandinavica%3A+Supplementum%22">Acta Neurologica Scandinavica: Supplementum</searchLink>. Dec2011 Supplement 192, Vol. 124, p29-35. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Vigabatrin%22">Vigabatrin</searchLink><br /><searchLink fieldCode="DE" term="%22Spasms%22">Spasms</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+of+epilepsy%22">Treatment of epilepsy</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+abuse%22">Drug abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Pure+Food+%26+Drug+Act+of+1906%22">Pure Food & Drug Act of 1906</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22United+States%22">United States</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Faught E. Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States. Acta Neurol Scand: 2011: 124 (Suppl. 192): 29-35. © 2011 John Wiley & Sons A/S. Vigabatrin is an antiepileptic drug used in more than 50 countries as adjunctive therapy for the treatment of refractory complex partial seizures (rCPS) in adults. First approved in the United Kingdom in 1989, vigabatrin was approved for use in the United States by the Food and Drug Administration in 2009. Although most clinical trials of vigabatrin have been conducted in Europe, three major trials, including two pivotal trials, were conducted in the United States. These trials have demonstrated efficacy and tolerability findings similar to those observed from the European trials. Results of the US trials have demonstrated vigabatrin to be an effective and generally well-tolerated therapy for rCPS in adults, with an optimal dosage of 3 g/day for most patients, and an onset of response generally within 2 weeks. This review focuses on the design and results of the three major US trials of vigabatrin in adults with rCPS. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Acta Neurologica Scandinavica: Supplementum is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=67057761
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/j.1600-0404.2011.01598.x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 29
    Subjects:
      – SubjectFull: Vigabatrin
        Type: general
      – SubjectFull: Spasms
        Type: general
      – SubjectFull: Treatment of epilepsy
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Drug abuse
        Type: general
      – SubjectFull: Pure Food & Drug Act of 1906
        Type: general
      – SubjectFull: United States
        Type: general
    Titles:
      – TitleFull: Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Faught, E.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2011 Supplement 192
              Type: published
              Y: 2011
          Identifiers:
            – Type: issn-print
              Value: 00651427
          Numbering:
            – Type: volume
              Value: 124
          Titles:
            – TitleFull: Acta Neurologica Scandinavica: Supplementum
              Type: main
ResultId 1